

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032935 A1

- (51) International Patent Classification⁷: A61K 31/502 (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (21) International Application Number: PCT/EP2003/011084 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (22) International Filing Date: 7 October 2003 (07.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0223341.9 8 October 2002 (08.10.2002) GB (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).
- (71) Applicant (*for all designated States except US*): ACADEMISCH ZIEKENHUIS GRONINGEN [NL/NL]; Hanzeplein 1, NL-9700 RB Groningen (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): DE BONT, Eveline, S., J., M. [NL/NL]; Esserlaan 10, NL-9722 SL Groningen (NL). KAMPS, Willem, A. [NL/NL]; Overtocht 21, NL-9951 LM Winsum (NL).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TREATMENT OF AML



(I)

(57) **Abstract:** The present Invention relates to a method of treating a warm-blooded animal having acute myeloid leukemia (AML) which is resistant to conventional chemotherapy, comprising administering to said animal a therapeutically effective amount of a compound of formula (I), wherein the radicals and symbols have the meanings as defined in the specification, together or in combination with a conventional compound or compound mixture useful in AML treatment, in particular

a topoisomerase II inhibitor, an antimetabolite, or an antitumor antibiotic, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said combination.

WO 2004/032935 A1